CN114533825A - Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof - Google Patents
Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof Download PDFInfo
- Publication number
- CN114533825A CN114533825A CN202210155720.XA CN202210155720A CN114533825A CN 114533825 A CN114533825 A CN 114533825A CN 202210155720 A CN202210155720 A CN 202210155720A CN 114533825 A CN114533825 A CN 114533825A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- compound
- inflammatory
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 130
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 15
- 239000002781 deodorant agent Substances 0.000 title claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 235000008632 Santalum album Nutrition 0.000 claims abstract description 17
- 244000166675 Cymbopogon nardus Species 0.000 claims abstract description 16
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 16
- 235000010254 Jasminum officinale Nutrition 0.000 claims abstract description 16
- 239000010664 perilla essential oil Substances 0.000 claims abstract description 15
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 14
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 14
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 230000001877 deodorizing effect Effects 0.000 claims abstract description 6
- 240000000513 Santalum album Species 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims abstract 3
- 241000207840 Jasminum Species 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 2
- 240000005385 Jasminum sambac Species 0.000 abstract 1
- 241000221035 Santalaceae Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010021639 Incontinence Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an anti-inflammatory and deodorant compound essential oil for sanitary products, and a preparation method and application thereof. The method comprises the following preparation raw materials: mint essential oil, cassia twig essential oil, perilla essential oil, sandalwood essential oil, citronella essential oil, jasmine essential oil and organic alcohol. The preparation method comprises the step of uniformly mixing the preparation raw materials according to the proportion. The essential oil provided by the invention is extracted from plant essential oil containing natural active ingredients, the raw materials are rich, and the formula proportion is scientific. The whole formula can clear heat, eliminate dampness, sooth liver, regulate qi and play a role in resisting inflammation and deodorizing together. Experimental research shows that the anti-inflammatory effect is obvious.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to anti-inflammatory and deodorant compound essential oil for sanitary products, and a preparation method and application thereof.
Background
The old, the patient and other people can continuously decline various functions of the human body due to the reasons of age increase, inconvenient movement, long-term bed rest and the like, the nerve and endocrine functions are obviously reduced, and then the function of controlling urine excretion is reduced, and the phenomenon of incontinence is caused. The sanitary product is used by incontinence people for a long time, so that the skin is exposed to irritants such as urine, excrement and the like for a long time, and then the skin keratinocytes are induced to release inflammation, chemotactic cytokines and growth factors, and the leukocytes are promoted to infiltrate into the epidermis to cause the skin inflammation. The skin inflammation further causes the symptoms of pruritus, pain and the like of the patient, even serious patients have chain reactions of nausea, vomit, diarrhea, headache and the like, so that the resistance of the patient is reduced, the condition of the patient is aggravated, and a vicious circle is formed. And the urine and the excrement can generate hydrogen sulfide, methyl mercaptan, aldehydes and other odor molecules to generate peculiar smell, so that the normal life of people is seriously influenced. The traditional Chinese medicine considers that the odor is mainly caused by dysfunction of viscera and disharmony of qi and blood, which are caused by pathogenic wind, body fluid accumulation and stasis and internal dampness and heat accumulation. Therefore, it is suitable for clearing heat and resolving dampness, and removing odor and aroma.
The aromatic essential oil is a volatile substance obtained by processing and extracting aromatic plants, has aromatic smell, can cover peculiar smell, and has various pharmacological actions such as anti-inflammation, bacteriostasis, emotion regulation and the like. The essential oil molecules can enter the blood circulation of a human body through skin and mucous membrane tissues and further act on target organs, so that the essential oil can be added into a sanitary product to prevent and treat skin inflammation of an incontinent patient. The research shows that the aromatic essential oil has obvious anti-inflammatory and deodorizing functions, can effectively prevent and treat inflammation and cover peculiar smell generated by metabolites. For example, the cassia twig essential oil can obviously inhibit the mouse auricle swelling caused by xylene and obviously reduce the total number of peripheral blood leucocytes and lymphocytes of a rat with an acute pneumonia model caused by Lipopolysaccharide (LPS); the osmanthus essential oil and the rose essential oil are common essential oils of the deodorant. The invention provides the anti-inflammatory and deodorant compound essential oil which can be used for sanitary products, has safe source, quick absorption and obvious effect, and can meet the requirements of users.
Disclosure of Invention
The invention aims to provide the anti-inflammatory and deodorizing compound essential oil with definite effect, which can be used for sanitary products, and the preparation method and the application thereof. The essential oil provided by the invention is extracted from plants containing natural active ingredients, has scientific formula and proportioning, has obvious anti-inflammatory and deodorizing effects, can effectively relieve inflammatory symptoms caused by incontinence, and can cover odor generated by incontinence.
The invention discloses an anti-inflammatory and deodorant compound essential oil for sanitary products in a first aspect, which comprises the following preparation raw materials: peppermint essential oil, cassia twig essential oil, perilla essential oil, sandalwood essential oil, citronella essential oil and jasmine essential oil, and organic alcohol dilution.
In some embodiments, the following raw materials are included in parts by weight: 10-30 parts of mint essential oil, 1-15 parts of cassia twig essential oil, 1-15 parts of perilla essential oil, 1-10 parts of sandalwood essential oil, 1-10 parts of citronella essential oil and 1-5 parts of jasmine essential oil, and ethanol or isopropanol is diluted.
In some embodiments, the following raw materials are included in parts by weight: 10-20 parts of mint essential oil, 1-10 parts of cassia twig essential oil, 1-10 parts of perilla essential oil, 2-8 parts of sandalwood essential oil, 2-8 parts of citronella essential oil and 1-3 parts of jasmine essential oil, and 1000 parts of 95% ethanol for dilution.
In some embodiments, the following raw materials are included in parts by weight: 15 parts of mint essential oil, 7.5 parts of cassia twig essential oil, 5 parts of perilla essential oil, 2.5 parts of sandalwood essential oil, 2.5 parts of citronella essential oil, 1 part of jasmine essential oil and 1000 parts of 95% ethanol for dilution.
The second aspect of the invention provides a preparation method of the compound essential oil, which is characterized in that the compound essential oil can be obtained by uniformly mixing the preparation raw materials.
The third aspect of the invention provides compound essential oil which is characterized by being prepared according to the preparation method.
The fourth aspect of the invention provides the use of the compound essential oil, which is characterized in that the compound essential oil is used for anti-inflammation and/or deodorization.
The fifth aspect of the invention provides the application of the compound essential oil in preparing anti-inflammatory drugs.
The sixth aspect of the invention provides an anti-inflammatory drug, which is characterized by comprising the compound essential oil. The anti-inflammatory agent may also include pharmaceutically acceptable excipients.
Compared with the prior art, the invention has the following technical advantages:
(1) the essential oil provided by the invention is extracted from plant essential oil containing natural active ingredients, the raw materials are rich, and the formula proportion is scientific.
(2) The mint in the compound essential oil is a monarch drug and has the effects of dispelling wind and heat and promoting eruption. Jasmine opens the depressed vital energy and clears away dirt, promotes diuresis, and cassia twig relieves exterior syndrome and dispels cold, warms and dredges channels and collaterals, and is used as a ministerial drug to play the effects of eliminating dampness and promoting qi circulation. The perilla and the sandalwood which are adjuvant drugs play roles of regulating qi and harmonizing stomach together, and the sandalwood can assist the cassia twig to relieve exterior syndrome. The citronella can dispel wind, release exterior syndrome, remove stasis and dredge collaterals. The whole formula can clear heat, eliminate dampness, sooth liver, regulate qi and play a role in resisting inflammation and deodorizing together.
(3) Experimental research shows that the compound essential oil IC provided by the invention50The value can reach 52.98 mu g/mL, and the anti-inflammatory effect is obvious.
(4) The preparation method is simple, does not need a complex preparation process, and is economic and environment-friendly.
(5) The compound essential oil has safe source, quick absorption and obvious effect, and can meet the requirements of users.
Drawings
FIG. 1 is a graph of cytotoxicity data of the compound essential oil of example 5 on RAW264.7 macrophages
Fig. 2 is a data plot of the effect of the compound essential oil of example 5 on NO production by lipopolysaccharide-induced RAW264.7 macrophages.
Fig. 3 is a dose-response graph of the effect of the compound essential oil of example 5 on NO production by lipopolysaccharide-induced RAW264.7 macrophages. Compared to the control group, (## P < 0.001); compared to the model group, (. P <0.05,. P <0.01,. P < 0.001).
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
Example 1
Taking 10 parts by weight of mint essential oil, 1 part by weight of cassia twig essential oil, 1 part by weight of perilla essential oil, 1 part by weight of sandalwood essential oil, 1 part by weight of citronella essential oil, 1 part by weight of jasmine essential oil and 1000-plus 2000 parts of 95% ethanol, and uniformly mixing to obtain the compound essential oil.
Example 2
Taking 20 parts by weight of mint essential oil, 10 parts by weight of cassia twig essential oil, 10 parts by weight of perilla essential oil, 8 parts by weight of sandalwood essential oil, 8 parts by weight of citronella essential oil, 3 parts by weight of jasmine essential oil and 1000 parts of 95% ethanol, and uniformly mixing to obtain the compound essential oil.
Example 3
Taking 20 parts by weight of mint essential oil, 10 parts by weight of cassia twig essential oil, 10 parts by weight of perilla essential oil, 8 parts by weight of sandalwood essential oil, 8 parts by weight of citronella essential oil, 3 parts by weight of jasmine essential oil and 1000 parts of 75% ethanol, and uniformly mixing to obtain the compound essential oil.
Example 4
Taking 20 parts by weight of mint essential oil, 10 parts by weight of cassia twig essential oil, 10 parts by weight of perilla essential oil, 8 parts by weight of sandalwood essential oil, 8 parts by weight of citronella essential oil, 3 parts by weight of jasmine essential oil and 1000-plus 2000 parts of 95% isopropyl alcohol, and uniformly mixing to obtain the compound essential oil.
Example 5
Taking 15 parts by weight of mint essential oil, 7.5 parts by weight of cassia twig essential oil, 5 parts by weight of perilla essential oil, 2.5 parts by weight of sandalwood essential oil, 2.5 parts by weight of citronella essential oil, 1 part by weight of jasmine essential oil and 1000 parts by weight of 95% ethanol, and uniformly mixing to obtain the compound essential oil.
Example 6
30 parts of mint essential oil, 15 parts of cassia twig essential oil, 15 parts of perilla essential oil, 10 parts of sandalwood essential oil, 10 parts of citronella essential oil, 5 parts of jasmine essential oil and 1000 parts of 95% ethanol are uniformly mixed to obtain the compound essential oil.
Example 7
Anti-inflammatory experiments:
(1) MTT experiment is used for determining the cytotoxicity of the compound essential oil prepared in example 5 on RAW264.7 cells, and the specific embodiment is as follows:
RAW264.7 cells were aspirated from the culture flask, and added to DMEM medium containing 10% FBS to prepare a cell suspension, to which a plating concentration of 7X 10 cells was applied4The cells/mL were seeded in 96-well plates (100. mu.L/well) in 5% CO2And culturing at 37 ℃ for 24 h. After 24h, the medium was discarded, and 100. mu.L of DMEM complete medium was added to the control group and the model group (lipopolysaccharide group). The administration group is provided with compound essential oil with concentration of 1/64, 1/96, 1/128, 1/256, 1/512, 1/1024, 1/2048 and 1/4096 of the original formula, and each concentration is provided with 5 compound holes. 5% CO2After 24 hours of incubation at 37 ℃, the medium was carefully aspirated, and 100. mu.L of MTT solution (0.5mg/mL) prepared in serum-free medium was added to each well; after further incubation for 4h, the culture medium was carefully aspirated from the wells. Add 150. mu.L DMSO/well and shake for 10min to dissolve the crystals well. The absorbance of each well at 490nm was measured using a microplate reader.
The results of the experiment are shown in FIG. 1. From fig. 1, it can be seen that the original recipe concentration dilution of 64-4096 times has no significant toxicity to RAW264.7 cells.
(2) The Griess experiment is used for determining the influence of the compound essential oil described in example 5 on NO production of RAW264.7 cells induced by lipopolysaccharide, and the specific embodiment is as follows:
the RAW264.7 cells were blown out from the culture flask, and added to DMEM medium containing 10% FBS to prepare a cell suspension, to which a plating concentration of 7X 10 was applied4The cells/mL were seeded in 96-well plates (100. mu.L/well) in 5% CO2And culturing at 37 ℃ for 24 h. After 24h, the medium was discarded, and 100. mu.L of DMEM complete medium was added to the control group and the model group (lipopolysaccharide group). The administration group comprises 1/64, 1/96, 1/128, 1/256, 1/512, 1/1024, 1/2048 and 1/4096 with concentration of compound essential oil as original formula, and is placed at 37 deg.C and 5% CO2Culturing in an incubator, and after 24h, adding 50 μ L of supernatant to another 96 wellsIn the plate, 50. mu.L of Griess R was added to each well1Reagent and 50. mu.L Griess R2And (4) incubating the reagent at room temperature. After 5min, detecting absorbance value at 540nm wavelength with enzyme-labeled photometer, wherein NO concentration is according to NaNO2The standard curve is calculated.
The experimental result is shown in fig. 2, and it can be seen from fig. 2 that the concentration of the original prescription diluted by 64-1024 times can significantly inhibit NO produced by RAW264.7 cells induced by lipopolysaccharide, and the anti-inflammatory effect is significant.
(3) According to the inhibition rate of the compound essential oil on NO, a dose-effect curve is drawn as shown in figure 3, and the IC of the essential oil formula50The value was 52.98. mu.g/mL.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. The anti-inflammatory and deodorant compound essential oil for the sanitary products is characterized by comprising the following preparation raw materials: peppermint essential oil, cassia twig essential oil, perilla essential oil, sandalwood essential oil, citronella essential oil and jasmine essential oil, and organic alcohol dilution.
2. The compound essential oil of claim 1, which comprises the following raw materials in parts by weight: 10-30 parts of mint essential oil, 1-15 parts of cassia twig essential oil, 1-15 parts of perilla essential oil, 1-10 parts of sandalwood essential oil, 1-10 parts of citronella essential oil, 1-5 parts of jasmine essential oil, and 1000 parts of ethanol or isopropanol.
3. The compound essential oil of claim 1, which comprises the following raw materials in parts by weight: 10-20 parts of mint essential oil, 1-10 parts of cassia twig essential oil, 1-10 parts of perilla essential oil, 2-8 parts of sandalwood essential oil, 2-8 parts of citronella essential oil and 1-3 parts of jasmine essential oil, and 1000 parts of 95% ethanol for dilution.
4. The compound essential oil of claim 1, which comprises the following raw materials in parts by weight: 15 parts of mint essential oil, 7.5 parts of cassia twig essential oil, 5 parts of perilla essential oil, 2.5 parts of sandalwood essential oil, 2.5 parts of citronella essential oil, 1 part of jasmine essential oil and 1000 parts of 95% ethanol for dilution.
5. A method for preparing the compound essential oil as claimed in any one of claims 1 to 4, which is characterized in that the preparation raw materials are uniformly mixed.
6. A compound essential oil characterized by being prepared according to the method of claim 5.
7. Use of a compound essential oil according to any one of claims 1 to 4 or 6, wherein the compound essential oil is used for anti-inflammatory and/or deodorizing.
8. Use of a compound essential oil according to any one of claims 1 to 4 or 6 in the preparation of an anti-inflammatory agent.
9. An anti-inflammatory agent comprising the compound essential oil of any one of claims 1 to 4 or 6.
10. The anti-inflammatory agent of claim 9, further comprising a pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210155720.XA CN114533825B (en) | 2022-02-21 | 2022-02-21 | Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210155720.XA CN114533825B (en) | 2022-02-21 | 2022-02-21 | Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114533825A true CN114533825A (en) | 2022-05-27 |
| CN114533825B CN114533825B (en) | 2023-02-10 |
Family
ID=81675554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210155720.XA Active CN114533825B (en) | 2022-02-21 | 2022-02-21 | Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114533825B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116196352A (en) * | 2022-09-07 | 2023-06-02 | 威高(北京)医疗科技有限公司 | Compound essential oil with effects of inducing resuscitation and refreshing mind and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2998478A1 (en) * | 2012-11-23 | 2014-05-30 | Oreal | Cosmetic use of a mixture of essential oils of lemon catnip, Citronella, clove, lemongrass, Melissa officinalis, green oregano, rosemary, mountain savory and thyme, as desquamating agent and for treating ichthyosis and atopic dermatitis |
| CN104815100A (en) * | 2015-05-15 | 2015-08-05 | 成都市康飞药业有限公司 | Composition with effects of refreshing and restoring consciousness and application thereof |
| CN106266685A (en) * | 2016-08-27 | 2017-01-04 | 广东罗浮山国药股份有限公司 | A kind of compound essential Oil and preparation method thereof |
-
2022
- 2022-02-21 CN CN202210155720.XA patent/CN114533825B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2998478A1 (en) * | 2012-11-23 | 2014-05-30 | Oreal | Cosmetic use of a mixture of essential oils of lemon catnip, Citronella, clove, lemongrass, Melissa officinalis, green oregano, rosemary, mountain savory and thyme, as desquamating agent and for treating ichthyosis and atopic dermatitis |
| CN104815100A (en) * | 2015-05-15 | 2015-08-05 | 成都市康飞药业有限公司 | Composition with effects of refreshing and restoring consciousness and application thereof |
| CN106266685A (en) * | 2016-08-27 | 2017-01-04 | 广东罗浮山国药股份有限公司 | A kind of compound essential Oil and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116196352A (en) * | 2022-09-07 | 2023-06-02 | 威高(北京)医疗科技有限公司 | Compound essential oil with effects of inducing resuscitation and refreshing mind and preparation method and application thereof |
| CN116196352B (en) * | 2022-09-07 | 2024-05-17 | 威高(北京)医疗科技有限公司 | Compound essential oil with effects of inducing resuscitation and refreshing mind and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114533825B (en) | 2023-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Anti-inflammatory and anti-ulcer activity of Calligonum comosum in rats | |
| CN100389814C (en) | Ointment for treating nervous damage and preparation method thereof | |
| CN114533825B (en) | Anti-inflammatory and deodorant compound essential oil for sanitary products and preparation method and application thereof | |
| Xi et al. | Protective effects of Erdosteine on interleukin-1β-stimulated inflammation via inhibiting the activation of MAPK, NF-κB, and Wnt/β-catenin signaling pathways in rat osteoarthritis | |
| CN108853183A (en) | A kind of antibacterial emulsifiable paste of Chinese mugwort and preparation method thereof | |
| CN112353877B (en) | Application of valerian total alkaloid extract in preparation of malassezia inhibitor | |
| CN105381352A (en) | Topical traditional Chinese medicine lotion for treating gynecological inflammation | |
| Eyong et al. | Chemical constituents, the stereochemistry of 3-hydroxy furonaphthoquinones from the root bark of Newbouldia laevis Seem (Bignoniaceae), and screening against Onchocerca ochengi parasites | |
| CN103041247B (en) | Traditional Chinese medicine suppository for curing colpitis and preparation method thereof | |
| CN112220900A (en) | Antibacterial lotion and preparation method thereof | |
| US6992073B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN110623993A (en) | Compound nutritional tablet of traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| CN104324272A (en) | Traditional Chinese medicine composition for treating canine parvovirus disease | |
| CN104398643B (en) | A kind of Chinese medicine composition for treating dermatitis and eczema | |
| Paswan et al. | Assessment of toxicity and wound healing activity of Selaginella Bryopteris extract | |
| CN1853708B (en) | Use of Galangal fruit and its extract in pharmacy | |
| Savych et al. | Investigation of pharmacological activity the new antidiabetic plant gathering in streptozotocin-nicotinamide-induced diabetes in the rats | |
| CN110279757A (en) | Weight reducing compound and preparation method thereof | |
| CN111840399A (en) | Male private part nursing composition and preparation method thereof | |
| CN103055192B (en) | Women inflammation recovery chewable tablet | |
| CN103599281B (en) | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof | |
| CN102526266B (en) | Chinese medicinal preparation for treating vaginitis and preparation method thereof | |
| CN108703963B (en) | Application of anethole in preparing medicine for treating neuropathic pain | |
| Yesmin et al. | The Anti-Inflammatory Effects of Spinacia Oleracea Leaf Extract on Carrageenan Induced Inflammation in Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240110 Address after: No. 1 Weigao Road, Torch High tech Industrial Development Zone, Weihai City, Shandong Province, 264200 Patentee after: WEIHAI WEGO MEDICAL MATERIALS CO.,LTD. Address before: Room 2-4, floor 2, No. 2-5, building 2, No. 9, Nanhu South Road, Chaoyang District, Beijing 100102 Patentee before: Weigao (Beijing) Medical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |